A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.
作者信息
Christopoulos Petros, Thomas Michael
机构信息
Department of Thoracic Oncology, Thoraxklinik at the Heidelberg University Medical Center, Heidelberg, Germany.
Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg, Germany.
出版信息
J Thorac Dis. 2017 Mar;9(3):E292-E294. doi: 10.21037/jtd.2017.02.86.
Abstract
摘要
相似文献
1
A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.在非小细胞肺癌（NSCLC）快速发展的检查点抑制领域中的一棵参天大树。
J Thorac Dis. 2017 Mar;9(3):E292-E294. doi: 10.21037/jtd.2017.02.86.
2
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.肿瘤蛋白 p53 和共济失调毛细血管扩张突变与非小细胞肺癌患者免疫检查点抑制剂反应和死亡率的关联。
JAMA Netw Open. 2019 Sep 4;2(9):e1911895. doi: 10.1001/jamanetworkopen.2019.11895.
3
Mighty theories from little acorns grow: is Lyme disease risk predictable from mast-seeding by oak trees?
Trends Ecol Evol. 1998 Aug 1;13(8):301-3. doi: 10.1016/s0169-5347(98)01400-1.
4
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.二线晚期非小细胞肺癌的显著进展：检查点抑制的快速发展领域。
J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16.
5
Combination approaches in NSCLC involving immune checkpoint inhibitors.非小细胞肺癌中涉及免疫检查点抑制剂的联合治疗方法。
Lung Cancer Manag. 2016 Dec;5(4):163-171. doi: 10.2217/lmt-2016-0013. Epub 2016 Nov 3.
6
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.非小细胞肺癌中的新型程序性死亡受体1配体（PD-L1）抑制剂——阿替利珠单抗的影响
Lung Cancer (Auckl). 2017 Jul 13;8:67-78. doi: 10.2147/LCTT.S113177. eCollection 2017.
7
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].[PD-1/PD-L1检查点抑制剂治疗非小细胞肺癌的临床研究进展]
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):440-448. doi: 10.3779/j.issn.1009-3419.2019.07.06.
8
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.阿替利珠单抗治疗晚期 NSCLC 进展后：来自随机、III 期 OAK 研究的结果。
J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.
9
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.破解生物标志物密码：晚期 NSCLC 中的 PD-L1 表达和检查点抑制。
Cancer Treat Rev. 2018 Apr;65:65-77. doi: 10.1016/j.ctrv.2018.02.005. Epub 2018 Feb 22.
10
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.晚期黑色素瘤中的检查点抑制剂：对免疫治疗领域的影响。
Expert Rev Anticancer Ther. 2017 Jul;17(7):647-655. doi: 10.1080/14737140.2017.1341315. Epub 2017 Jun 19.
引用本文的文献
1
Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.中国新疆非小细胞肺癌人群中 KRAS 突变亚型的临床特征及其对免疫治疗预后的影响。
J Cancer Res Clin Oncol. 2024 Sep 7;150(9):413. doi: 10.1007/s00432-024-05932-x.
本文引用的文献
1
Programmed death of chemotherapy in non-small-cell lung cancer?非小细胞肺癌化疗中的程序性死亡？
Lancet. 2017 Jan 21;389(10066):227-228. doi: 10.1016/S0140-6736(16)32535-1. Epub 2016 Dec 13.
2
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
3
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.PD-L1 免疫组织化学检测在肺癌中的应用：蓝图 PD-L1 IHC 检测比较项目第一阶段的结果。
J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.
4
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
5
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.纳武利尤单抗对比多西他赛用于含 PD-L1 检测的晚期非鳞状 NSCLC 的成本效果分析。
J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14.
6
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.癌症患者使用抗 PD-1 药物纳武利尤单抗和帕博利珠单抗的经济可持续性：最新见解和未来挑战。
Cancer Treat Rev. 2016 Jul;48:20-4. doi: 10.1016/j.ctrv.2016.06.002. Epub 2016 Jun 7.
7
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
8
CANCER IMMUNOLOGY. The "cancer immunogram".癌症免疫学。“癌症免疫图谱”。
Science. 2016 May 6;352(6286):658-60. doi: 10.1126/science.aaf2834.
9
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.阿特珠单抗对比多西他赛用于治疗既往接受过治疗的非小细胞肺癌患者（POPLAR）：一项多中心、开放标签、2 期随机对照临床试验。
Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
10
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
Zotero 插件